Boundless Bio logo
Boundless Bio
BOLD | NASDAQ
Chart Builder DCF Calculator
$2.41
-$0.09 (-3.60%)
At close: Nov 16, 2026, 4:00 PM ET
$2.39
-$0.02 (-0.83%)
After-hours: Nov 16, 2026, 6:23 PM ET

Boundless Bio Company Profile

Company profile explained

Company Profile

Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.

Key Executives

Name Position
Jessica Oien President, Principal Executive Officer, Chief Legal Officer & Corporate Secretary
David Hinkle Senior Vice President of Finance, Controller & Corporate Treasurer
Meredith Wesley Chief Human Resources Officer

Latest SEC Filings

Date Type Title
Oct 29, 2026 4 Filing
Oct 26, 2026 425 Filing
Oct 26, 2026 4 Filing
Oct 26, 2026 425 Filing
Oct 20, 2026 4 Filing
Oct 08, 2026 S-4 Filing
Aug 28, 2026 425 Filing
Aug 28, 2026 8-K Current Report
Aug 28, 2026 4 Filing
Aug 27, 2026 SC 13G Statement of acquisition of beneficial ownership b...
View All SEC Filings ➞
Boundless Bio
Boundless Bio logo
Country United States
IPO Date Mar 28, 2024
Industry Biotechnology
Sector Healthcare
Employees 28
CEO Zachary Hornby

Contact Details

10955 Alexandria Way San Diego, California 92121 United States

Stock Details

Ticker Symbol BOLD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001782303
CUSIP Number 10170A100
ISIN Number US10170A1007
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.